Know Cancer

or
forgot password

Safety and Efficacy of Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants


Phase 1/Phase 2
3 Years
65 Years
Open (Enrolling)
Both
Graft Versus Host Disease

Thank you

Trial Information

Safety and Efficacy of Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants

Inclusion Criteria


Eligible for full intensity bone marrow transplant (BMT) conditioning but who lack a 6/6
HLA idential sibling donor

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Prevention

Principal Investigator

John Levine, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Univeristy of Michigan

Authority:

United States: Food and Drug Administration

Study ID:

2146

NCT ID:

NCT00056875

Start Date:

September 2002

Completion Date:

April 2004

Related Keywords:

  • Graft Versus Host Disease
  • graft versus host disease
  • bone marrow transplant
  • alternative donor
  • Graft vs Host Disease

Name

Location

University of Michigan Cancer CenterAnn Arbor, Michigan  48109